According to the World Health Organization, the abusive consumption of certain drugs and substances has increased in recent years, generating serious consequences for the population: neurological damage, motor disabilities, addiction, overdoses, and death. While traditional pharmaceutical forms such as tablets are most frequently abused, transdermal patches — especially those containing opioids — must also be considered in this context.
Health agencies such as the Food & Drug Administration (FDA) endorse the implementation of measures to assess various aspects that prevent and discourage medication abuse. These measures span from packaging and labeling to storage, disposal, and product formulation.
What Is an Abuse Deterrent Formulation (ADF)?
In this context, an Abuse Deterrent Formulation (ADF) is defined as a strategy that can be implemented to make drug abuse more challenging or less appealing for those attempting to use the medication outside of approved conditions.
ADFs are not exclusive to active ingredient formulation — they can be applied at multiple levels of the product lifecycle, from pre-marketing studies through post-marketing surveillance.
Studies for ADF Strategy Development and Evaluation
Pre-marketing studies
Pre-marketing studies, conducted before the drug becomes available on the market, include:
- Research on the product’s clinical abuse potential.
- Studies on active ingredient extraction methods from the formulation.
- Various in vitro studies aimed at evaluating the system’s resistance to manipulation.
These studies allow anticipating the most probable abuse routes and the effects that medication misuse could generate, informing the design of deterrent strategies.
Post-marketing studies
Post-marketing studies provide specific information about real abuse cases once the product is on the market. They evaluate the effect of anti-abuse strategies implemented and provide data on the impact of those strategies on outcomes such as addiction, overdose, and death.
The combination of pre- and post-marketing evidence is the foundation for demonstrating to the FDA and other agencies that an ADF strategy is effective and clinically relevant.
ADF Strategies: A Summary by Application Level
Level of Application | Strategy | Example |
|---|---|---|
Administration | Physical barriers to misuse | Pre-filled syringes with exact dose; subcutaneous implants only manipulable in medical settings |
Formulation — physical barrier | Manipulation-resistant design | Tablets too resistant to be crushed |
Formulation — chemical barrier | Gelling agent | Prevention of inhalation or injection by forming gel when attempting to dissolve |
Formulation — aversive agent | Substance generating unpleasant reaction | Intense itching, bitterness, or vomiting induction when used outside approved conditions |
Formulation — antagonist agent | Target receptor blockade | Opioid antagonist blocking agonist effect if extracted and administered via different route |
ADF Strategies in Transdermal Patch Formulation
Deterrent strategies can be incorporated into both drug administration and formulation, adapting to the most prevalent abuse route depending on the molecule: inhalation, injection, or ingestion.
Aversive agent
The most common and easily implementable strategy in transdermal formulations is the inclusion of an aversive agent. Aversive agents are substances that cause an unpleasant reaction in the user — such as pronounced itching, intense bitterness, or vomiting induction — when the medication is used contrary to medical instructions.
This reaction occurs specifically outside approved use conditions: the medication correctly applied transdermally does not trigger the aversive response. This approach does not prevent abuse per se, but makes the experience less pleasant, reducing motivation for misuse.
Antagonist agent
Another way to implement an ADF is to include an antagonist agent in the formulation. To understand this mechanism, it is important to distinguish between agonists and antagonists:
- Agonists: substances that bind to specific cell receptors, producing physiological responses. In the case of opioids, the agonist produces the analgesic or euphoric effect sought by those who abuse the medication.
- Antagonists: substances that inhibit receptor activation, blocking the agonist’s action.
By including an antagonist in the patch formulation, the system is designed so that if the active ingredient is extracted and injected or inhaled, the antagonist is also present and blocks the desired effect. In correct transdermal administration, differential absorption of the antagonist through the skin ensures it does not interfere with the agonist’s therapeutic effect.
Regulatory and Development Considerations
The FDA has specific guidelines for the development and evaluation of ADF formulations, including the categorization of required studies based on the level of evidence and the predominant abuse route of the molecule. For opioid transdermal patches, the regulator expects both in vitro and in vivo evidence demonstrating the effectiveness of the strategies implemented.
For teams developing patches with molecules that have abuse potential, ADF strategy must be considered from early development stages. Formulation decisions that facilitate or hinder the implementation of these strategies are made during preformulation — incorporating them late may require complete reformulation.
